<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Treatment options for <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) are limited after a fluoropyrimidine, <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> and irinotecan; novel agents need to be explored in this setting </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="49375">Dasatinib</z:chebi>, an oral inhibitor of Src family kinases, inhibits proliferation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines and has antitumor activity in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: We conducted a multi-center phase II trial of <z:chebi fb="0" ids="49375">dasatinib</z:chebi> in unresectable, previously-treated metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
<SENT sid="3" pm="."><plain>No more than 2 prior chemotherapy regimens were permitted, which must have contained a fluoropyrimidine, <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> and irinotecan </plain></SENT>
<SENT sid="4" pm="."><plain>The primary endpoint was progression-free survival (PFS) at 4 months </plain></SENT>
<SENT sid="5" pm="."><plain>The Simon two-stage design required that at least 5 of the first 19 patients be progression-free at 4 months to expand to a second stage </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Nineteen patients enrolled at 9 centers </plain></SENT>
<SENT sid="7" pm="."><plain>The study was terminated after the first stage due to lack of efficacy </plain></SENT>
<SENT sid="8" pm="."><plain>There were no objective responses; 1 patient (5%) had stable disease for 7.3 months </plain></SENT>
<SENT sid="9" pm="."><plain>The PFS rate at 4 months was 5.3% (90% CI: 0.3, 22.6) </plain></SENT>
<SENT sid="10" pm="."><plain>Median PFS was 1.6 months (90% CI: 1.4, 1.8) </plain></SENT>
<SENT sid="11" pm="."><plain>Median overall survival was 5.1 months (90% CI: 2.4, 6.3) </plain></SENT>
<SENT sid="12" pm="."><plain>Grade 3/4 toxicities included <z:mp ids='MP_0002899'>fatigue</z:mp> in 16% of patients, and <z:hpo ids='HP_0001903'>anemia</z:hpo>, <z:hpo ids='HP_0002039'>anorexia</z:hpo>, <z:hpo ids='HP_0002018'>nausea</z:hpo>/<z:hpo ids='HP_0002013'>vomiting</z:hpo> and <z:hpo ids='HP_0002094'>dyspnea</z:hpo> in 11% </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSION: <z:chebi fb="0" ids="49375">Dasatinib</z:chebi> is inactive as a single agent in previously treated metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
</text></document>